Immix Biopharma (NASDAQ:IMMX) Trading Up 15.3% – Should You Buy?

Posted by Defense World Staff on May 23rd, 2025

Shares of Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report) were up 15.3% during trading on Thursday . The stock traded as high as $2.50 and last traded at $2.41. Approximately 3,883,331 shares were traded during mid-day trading, an increase of 2,729% from the average daily volume of 137,279 shares. The stock had previously closed at $2.09.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $7.00 target price on shares of Immix Biopharma in a research note on Monday, February 10th.

Read Our Latest Stock Analysis on IMMX

Immix Biopharma Trading Up 15.3%

The company has a market cap of $67.18 million, a price-to-earnings ratio of -2.84 and a beta of 0.27. The company’s 50 day moving average price is $1.82 and its 200 day moving average price is $1.91.

Immix Biopharma (NASDAQ:IMMX – Get Free Report) last released its earnings results on Monday, March 24th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.09. Sell-side analysts predict that Immix Biopharma, Inc. will post -0.87 earnings per share for the current year.

Hedge Funds Weigh In On Immix Biopharma

An institutional investor recently bought a new position in Immix Biopharma stock. SBI Securities Co. Ltd. purchased a new stake in Immix Biopharma, Inc. (NASDAQ:IMMX – Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 17,500 shares of the company’s stock, valued at approximately $38,000. SBI Securities Co. Ltd. owned approximately 0.06% of Immix Biopharma as of its most recent SEC filing. 11.26% of the stock is currently owned by institutional investors and hedge funds.

Immix Biopharma Company Profile

(Get Free Report)

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.